<DOC>
	<DOCNO>NCT01295489</DOCNO>
	<brief_summary>This research trial study biomarkers patient previously untreated invasive ovarian epithelial , fallopian tube , primary peritoneal cancer . Studying sample tumor tissue , peritoneal cavity fluid , blood patient receive chemotherapy directly abdominal cavity ( intraperitoneal ) may help doctor learn effect intraperitoneal chemotherapy cell . It may also help doctor identify learn biomarkers related cancer .</brief_summary>
	<brief_title>Biomarkers Patients With Previously Untreated Invasive Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility obtain peritoneal fluid , peritoneal washing , peripheral blood patient receive intraperitoneal ( IP ) chemotherapy ovarian cancer multiple institution . II . Assess recovery viability peripheral blood mononuclear cell immune cell subset peritoneal fluid washing . III . Assess amount peritoneal fluid obtain pre-treatment specified time point course IP chemotherapy . IV . Quantify type number cell peritoneal fluid , peritoneal washing , blood recover woman treatment platinum taxane base IP chemotherapy . V. Determine level immunomodulatory cytokine peritoneal fluid , peritoneal washing , blood recover woman treatment platinum taxane base IP chemotherapy . VI . Generate exploratory information impact platinum taxane base IP chemotherapy immunomodulatory cytokine tumor-associated alteration cell phenotype peritoneal fluid , peritoneal washing , blood . VII . To determine feasibility obtain peritoneal fluid , peritoneal washing , peripheral blood patient receive intravenous ( IV ) chemotherapy ovarian cancer multiple institution ( limited patient receive IP catheter time surgery catheter leave investigator , subsequently treat IV chemotherapy ) . VIII . Assess amount peritoneal fluid obtain pre-treatment specified time point course IV chemotherapy . IX . Assess recovery viability peripheral blood mononuclear cell immune cell subset peritoneal fluid washing . X . Quantify type number immune cell peritoneal fluid , peritoneal washing , blood recover woman treatment platinum taxane base IV chemotherapy . XI . Determine level immunomodulatory cytokine peritoneal fluid , peritoneal washing , blood recover woman treatment platinum taxane-based IV chemotherapy . XII . Generate exploratory information impact platinum taxane base IV chemotherapy immunomodulatory cytokine tumor-associated alteration cell phenotype peritoneal fluid , peritoneal washing , blood . XIII . Explore whether relationship immune cell population measure peripheral blood , peritoneal fluid , peritoneal washing AND immune cell subset measure immunohistochemistry archival formalin-fixed , paraffin-embedded tumor tissue . OUTLINE : Patients assign group base arm treatment randomize receive Gynecologic Oncology Group ( GOG ) -0252 . GROUP A ( IP CATHETER REMOVED ) : Archival formalin-fixed , paraffin-embedded tumor ( collect previous surgery ) , peritoneal fluid , peritoneal wash , blood ( cell , plasma , serum isolation ) sample collect course one blood ( cell , plasma , serum isolation ) collect course two three translational research . GROUP B ( IP CATHETER IN PLACE ) : Archival formalin-fixed , paraffin-embedded tumor ( collect previous surgery ) , peritoneal fluid , peritoneal wash , blood ( cell , plasma , serum isolation ) sample collect course one peritoneal fluid , peritoneal wash , blood ( cell , plasma , serum isolation ) course two three translational research .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Patients must enrol GOG0252 Patients must IP catheter place prior initiate platinum taxanebased chemotherapy GOG0252 Patients must sign approve informed consent specimen collection participation translational research study Patients enrol GOG0252 Patients IP catheter place prior initiate platinum taxanebased IP chemotherapy GOG0252 Patients sign approve informed consent specimen collection participation translational research study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>